Browsing Tag
ENROLL-HD
1 post
uniQure faces key regulatory test as investors weigh AMT-130’s mixed long-term clinical data
uniQure stock reverses gains despite FDA priority review for AMT-130. Explore its $810M cash position, clinical risks and May 2027 decision.